In response to the ongoing shortage of ADHD medications, the U.S. Food and Drug Administration (FDA) has approved several generic versions of Vyvanse (lisdexamfetamine dimesylate) for the treatment of attention-deficit/hyperactivity disorder in people 6 years and older.
Vyvanse is available in capsules and chewable tablets, according to the FDA’s announcement.
Dr. Barry K. Herman, a board-certified psychiatrist and the chief medical officer for Mentavi Health, a mental health assessment provider in Grand Rapids, Michigan, is hopeful that these new generic drugs will help address the persistent ADHD medication shortage.